In a nutshell This study was carried out to look at the effectiveness of immune checkpoint inhibitors (ICI) in non-small cell cancer (NSCLC) patients with different sites of cancer spread. The authors found that ICIs could significantly improve the overall survival (OS) of patients NSCLC spread to the brain or liver compared to conventional...
Read More
In a nutshell This trial is being carried out to examine the effectiveness of a new immune therapy, zimberelimab, alone or in combination with other immune therapies (domvanalimab and etrumadenant) in patients with PD-L1 positive non-small cell lung cancer (NSCLC). The main outcomes to be measured in this trial is the response rate and survival...
Read More
In a nutshell This trial is being carried out to assess the safety and effectiveness of an experimental drug called BCA101 alone and in combination with pembrolizumab (Keytruda) in advanced solid tumors that are EGFR-positive. The main outcomes to be measured are the occurrence of side effects and response to treatment. The details Advanced solid...
Read More
In a nutshell This trial is looking at the effectiveness of Quad Shot (QS) radiation therapy (RT) to relieve symptoms in patients with advanced non-small-cell lung cancer (NSCLC). The main outcome that is to be measured is the occurrence of side effects over the course of 3-months. This trial is being carried out in New Jersey and New York,...
Read More
In a nutshell This trial is looking at the effectiveness, safety, and tolerability of ladiratuzumab vedotin (LV) in patients with advanced solid tumors, including lung cancer. The main outcome to be measured in this trial is the response rate to the new drug. The details Advanced tumors have spread from the organ where they originated. These tumors...
Read More
In a nutshell This study looked at the safety and effectiveness of atezolizumab (Tecentriq) compared to platinum-based chemotherapy for the treatment of advanced lung cancer. They found that atezolizumab improved survival compared to chemotherapy in these patients. Some background Lung cancer is classified based on how the tumor cells look...
Read More
In a nutshell This trial was carried out to assess the effectiveness and safety of osimertinib (Tagrisso) after surgery for EGFR-positive advanced non-small cell lung cancer (NSCLC). The trial found that this treatment improved the outcomes of patients with stage IB to IIIA EGFR-positive NSCLC that was surgically removed. Some...
Read More
In a nutshell This study investigated the antitumor activity, safety, and survival after nivolumab (Opdivo) and chemotherapy before surgery for patients with stage IIIA non-small-cell lung cancer (NSCLC). The study showed a high rate of survival without cancer worsening among these patients. Some background NSCLC amounts to over 80% of...
Read More
In a nutshell This trial was carried out to examine the effectiveness of osimertinib (Tagrisso) in non-small cell lung cancer (NSCLC) that has spread to the brain of the layers of the brain (meninges). The authors concluded that osimertinib showed improved survival and had a good response rate in these patients. Some...
Read More
In a nutshell This trial was carried out to examine the effectiveness and safety of selpercatinib (Retevmo) in treating RET-positive non-small-cell lung cancer (NSCLC). The authors concluded that selpercatinib had good effectiveness and low toxicity in these patients. Some background NSCLC is responsible for 85% of all lung cancer...
Read More
In a nutshell This article looked at the use of immune checkpoint inhibitors (ICIs) in the treatment of extensive-stage (ES) small cell lung cancer (SCLC). The authors found that the addition of atezolizumab (Tecentriq) or durvalumab (Imfinzi) to first-line platinum-based chemotherapy prolongs survival and improves the quality of life...
Read More
In a nutshell This trial is looking to examine the effectiveness of carboplatin (Paraplatin), paclitaxel (Taxol), and ramucirumab (Cyramza) in the treatment of advanced non-squamous non-small cell lung cancer (NSCLC) that is progressive after maintenance therapy. The main outcome that is to be measured is the response of the...
Read More
